Designed to be different:
Developing a potential best-in-class anti-OX40 treatment with features that matter to patients
ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients who have immunological, autoimmune and inflammatory diseases. Olevaprubart is our next-generation investigational anti-OX40 monoclonal antibody.
Olevaprubart
Olevaprubart is an extended half-life anti-OX40 monoclonal antibody in clinical development that targets and inhibits OX40 receptor signaling without depleting T cells for potential enhanced efficacy, safety, and patient convenience.
News
August 17, 2026